Analysts Remain Bullish On Cardlytics Post Q4 Results

Analysts reiterated a Buy on Cardlytics Inc CDLX post Q4 results.
Craig-Hallum analyst Jason Kreyer lowered the firm's price target on Cardlytics from $100 to $70 (15% upside) and kept a Buy.
The analyst notes quarterly results were strong despite lingering concerns over the supply chain, labor shortages, and omicron issues faced in the quarter.
That said, management is leaning into the opportunity with direct investments into sales talent, engineering, and retention. The result is further delays in profitability, Kreyer notes.
Despite an outlook for substantially higher revenue this year, he adds that EBITDA losses will exceed last year to afford these investments.
Needham analyst Kyle Peterson maintained Cardlytics with a Buy and lowered the price target from $120 to $85 (39% upside).
Price Action: CDLX shares traded higher by 13.75% at $61.14 on the last check Wednesday.

Analyst Calendar